original ) (raw )A15 NDT atomoxetine treatment decreases striatal dopaminergic transp 111915
Ali Evren Tufan, M.D, Associate Professor , sevay alşen
View PDFchevron_right
Atomoxetine blocks motor hyperactivity in neonatal 6-hydroxydopamine-lesioned rats: implications for treatment of attention-deficit hyperactivity disorder
Ross Baldessarini
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP), 2005
View PDFchevron_right
Atomoxetine and Stroop Task Performance in Adult Attention-Deficit/Hyperactivity Disorder
Stephen V Faraone
Journal of Child and Adolescent Psychopharmacology, 2005
View PDFchevron_right
Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD
Nabeel Nabulsi
NeuroImage, 2014
View PDFchevron_right
Striatal Activation Predicts Differential Therapeutic Responses to Methylphenidate and Atomoxetine
Jin Fan
Journal of the American Academy of Child and Adolescent Psychiatry, 2017
View PDFchevron_right
The Dopamine Transporter and Attention-Deficit/Hyperactivity Disorder
Bertha Madras
Biological Psychiatry, 2005
View PDFchevron_right
A Review on Atomoxetine in the Treatment of Attention Deficit Hyperactivity Disorder
PENUGONDA VINEELA
African Journal of Psychiatry, 2014
View PDFchevron_right
Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using ( S , S )-[ 18 F]FMeNER-D 2
Balazs Gulyas
Psychopharmacology, 2006
View PDFchevron_right
Long-Term Stimulant Treatment Affects Brain Dopamine Transporter Level in Patients with Attention Deficit Hyperactive Disorder
James Swanson
PLoS ONE, 2013
View PDFchevron_right
Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat
Taiwo Sheikh
Neuropharmacology, 2006
View PDFchevron_right
Atomoxetine Increased Effect over Time in Adults with Attention‐Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double‐Blind, Placebo‐Controlled, Randomized Trials
David Clemow
CNS Neuroscience & Therapeutics, 2016
View PDFchevron_right
The dopamine transporter: relevance to attention deficit hyperactivity disorder (ADHD)
Bertha Madras
Behavioural Brain Research, 2002
View PDFchevron_right
Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice
Yukio Ago
Journal of neurochemistry, 2010
View PDFchevron_right
Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects
Kora Bruin
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2007
View PDFchevron_right
Atomoxetine for the Treatment of Attention Deficit Hyperactivity Disorder
Yanki Yazgan
2009
View PDFchevron_right
A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder
Todd Durell
Psychopharmacology, 2013
View PDFchevron_right
Neurophysiologic predictors of response to atomoxetine in young adults with attention deficit hyperactivity disorder: a pilot project
Ian Cook , Alexander Korb , Aimee Hunter
Journal of psychiatric research, 2014
View PDFchevron_right
Clinical Responses to Atomoxetine in Attention-Deficit/Hyperactivity Disorder: The Integrated Data Exploratory Analysis (IDEA) Study
Margaret D Weiss
Journal of the American Academy of Child & Adolescent Psychiatry, 2009
View PDFchevron_right
Therapeutic drug monitoring of atomoxetine in children and adolescents with attention-deficit/ hyperactivity disorder: a naturalistic study
Eberhard Schulz
Journal of Neural Transmission
View PDFchevron_right
Atomoxetine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Systematic Review of Review Papers 2009–2011. An Update for Clinicians
Chris Bushe
Journal of Central Nervous System Disease, 2011
View PDFchevron_right
Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study
J. Wernicke
Pediatrics, 2001
View PDFchevron_right
Atomoxetine response in the inattentive and combined subtypes of attention deficit hyperactivity disorder: a retrospective chart review
Elif Ercan
ADHD Attention Deficit and Hyperactivity Disorders, 2013
View PDFchevron_right
Further Evidence of Dopamine Transporter Dysregulation in ADHD: A Controlled PET Imaging Study Using Altropane
Darin Dougherty
Biological Psychiatry, 2007
View PDFchevron_right
A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD
Mats Johnson
European Child & Adolescent Psychiatry, 2004
View PDFchevron_right
A Pilot Study of Atomoxetine in Young Children with Attention-Deficit/Hyperactivity Disorder
Desiree Murray
Journal of Child and Adolescent Psychopharmacology, 2007
View PDFchevron_right